Next |
home / stock / pbyi / pbyi message board
Subject | By | Source | When |
---|---|---|---|
Awesome weekly chart | mitcheroo | investorshub | 01/26/2023 1:06:50 AM |
znewcar1: $PBYI 20% v1,3M c4.50 f45,6M H4.60 ML2.08 | znewcar1 | investorshangout | 11/22/2022 4:15:11 AM |
Oh man got caught up on the pump | Roadtojourney | investorshub | 01/12/2022 11:09:49 PM |
Historic short interest: | XenaLives | investorshub | 11/22/2021 2:12:16 PM |
Institutional Shares (Long) 36,969,527 - 90.42% (ex 13D/G) - | XenaLives | investorshub | 11/22/2021 2:10:05 PM |
$PBYI two conferences next week | CHARLIE125 | investorshub | 01/08/2021 9:08:36 AM |
$PBYI | CHARLIE125 | investorshub | 01/07/2021 3:40:43 PM |
$PBYI | CHARLIE125 | investorshub | 12/20/2020 8:53:14 PM |
PBYI | CHARLIE125 | investorshub | 12/19/2020 1:41:52 PM |
PBYI you can see last trade 1.3 billions | CHARLIE125 | investorshub | 12/19/2020 1:39:42 PM |
Historic short interest: | XenaLives | investorshub | 11/25/2020 7:26:02 AM |
Option chain 10/29 and 11/16 | XenaLives | investorshub | 11/16/2020 1:39:14 PM |
Blocks >= 5000 | XenaLives | investorshub | 11/12/2020 3:41:36 PM |
Blocks >= 5000 | XenaLives | investorshub | 10/20/2020 4:44:37 PM |
Blocks >= 5000 | XenaLives | investorshub | 09/16/2020 10:18:50 AM |
Block Trades >= 5000 | XenaLives | investorshub | 08/24/2020 9:07:13 PM |
Historic short interest: | XenaLives | investorshub | 08/20/2020 2:17:14 PM |
Puma Biotech ($PBYI) Tops Q2 Earnings and Revenue Estimates | XenaLives | investorshub | 08/07/2020 3:55:17 PM |
Two form 4's and a strange spike to | XenaLives | investorshub | 08/06/2020 12:24:20 AM |
Pipeline | XenaLives | investorshub | 06/18/2020 12:38:41 PM |
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000 ® Index at the conclusion of Russell Investments’ annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S....